Alterity Therapeutics (ATHE) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alterity Therapeutics has announced that its Phase 2 clinical trial of ATH434 for early-stage multiple system atrophy (MSA) will continue as recommended by the independent Data Monitoring Committee, which found no safety concerns. The trial is expected to be completed by November 2024, with top-line data anticipated in January 2025. ATH434 is an oral agent aimed at inhibiting the aggregation of neurodegenerative proteins and has already shown promise in Phase 1 studies.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
